NCT04659005

Brief Summary

Hepatocellular carcinoma (HCC) is a common malignancy with poor prognosis worldwide. The asymptomatic of early-stage HCC may lead most patients diagnosed at advanced stages. This highlights the importance of HCC screening among high-risk populations to detect HCC at early stages and achieve better survival. Hepatitis B virus (HBV) infection is a major cause of HCC in China, but the utilization of HCC screening is suboptimal among patients with HBV infection. Currently, there are no-theory based intervention, to our knowledge, has been reported to improve HCC screening decision-making and uptake among patients with HBV infection . Therefore, based on our previous systematic review, the current study has proposed a nurse-led decision counseling program to improve decision-making and uptake of HCC screening among patients with HBV infection in mainland China. Participants in intervention group will receive nurse-led decision counseling. The intervention components include 40-minute education and tailored information regarding HCC screening. At the second week, decision support will be provided through 30-minute telephone call. At the third week, another telephone call (20 minutes) will be provided to help participants identify and address barriers to HCC screening. Participants in control group will receive usual care. After the intervention and at 3-month follow-up, the study will collect data related to HCC screening uptake rates. Findings are paramount to promote informed choice in HCC screening and early HCC detection to improve survival outcomes among patients with HBV infection.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
178

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Feb 2021

Geographic Reach
1 country

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 31, 2020

Completed
1 month until next milestone

First Posted

Study publicly available on registry

December 9, 2020

Completed
2 months until next milestone

Study Start

First participant enrolled

February 1, 2021

Completed
12 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 20, 2022

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

February 28, 2022

Completed
Last Updated

April 6, 2022

Status Verified

March 1, 2022

Enrollment Period

12 months

First QC Date

October 31, 2020

Last Update Submit

March 27, 2022

Conditions

Keywords

Hepatocellular carcinomaHepatitis BScreeningEarly detectionNurse-led interventionDecision counseling

Outcome Measures

Primary Outcomes (1)

  • HCC screening uptake rates

    The liver ultrasound, serum alpha-fetoprotein, dynamic computed tomography, and magnetic resonance are all considered as screening tests in the current study.

    Immediately after intervention and three months after intervention

Secondary Outcomes (3)

  • HCC screening knowledge questionnaire

    Baseline, immediately after intervention and three months after intervention

  • Preventive health model construct instrument.

    Baseline, immediately after intervention and three months after intervention

  • Decisional conflict scale

    Baseline, immediately after intervention and three months after intervention

Study Arms (2)

Nurse-led decision counseling group

EXPERIMENTAL

Provide education, tailored information, decision support, and psychosocial support regarding hepatocellular carcinoma screening

Other: Nurse-led decision counseling

Control group

OTHER

Usual care provided by the hospital, including one-page written education information about diet, medications, and daily exercises.

Other: Usual care

Interventions

Provide education, tailored information, decision support, and psychosocial support regarding hepatocellular carcinoma screening

Nurse-led decision counseling group

Usual care provided by the hospital, including one-page written education information about diet, medications, and daily exercises

Control group

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • patients with HBV infection (HBsAg positive), aged 18-65 years old
  • have been recommended to have HCC screening, including liver cirrhosis, males over age 40, women over age 50, and family history of HCC
  • can understand Chinese

You may not qualify if:

  • have comorbid condition, including co-infection with hepatitis C, human immunodeficiency virus, and alcoholic liver disease
  • have hepatocellular carcinoma diagnosis
  • have undergone liver transplantation
  • have encephalopathy
  • not willing to participate

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Henan Provincial People's Hospital

Zhengzhou, Henan, China

Location

The Nethersole School of Nursing, The Chinese University of Hong Kong

Hong Kong, Hong Kong, China

Location

Related Publications (2)

  • Li C, Lu X, Xu J, Gao F, Lee E, Chan CWH. Effectiveness of a nurse-led decision counselling programme on hepatocellular carcinoma screening uptake among patients with hepatitis B: A randomised controlled trial. Int J Nurs Stud. 2023 Dec;148:104610. doi: 10.1016/j.ijnurstu.2023.104610. Epub 2023 Sep 21.

  • Li C, Lu X, Gao F, Lee E, Chan CWH. Development of a nurse-led decision counseling program for improving hepatocellular carcinoma screening: A typology-guided feasibility study. Asia Pac J Oncol Nurs. 2023 Mar 9;10(6):100215. doi: 10.1016/j.apjon.2023.100215. eCollection 2023 Jun.

Related Links

MeSH Terms

Conditions

Hepatitis BCarcinoma, Hepatocellular

Condition Hierarchy (Ancestors)

Blood-Borne InfectionsCommunicable DiseasesInfectionsHepadnaviridae InfectionsDNA Virus InfectionsVirus DiseasesHepatitis, Viral, HumanHepatitisLiver DiseasesDigestive System DiseasesAdenocarcinomaCarcinomaNeoplasms, Glandular and EpithelialNeoplasms by Histologic TypeNeoplasmsLiver NeoplasmsDigestive System NeoplasmsNeoplasms by Site

Study Officials

  • Caixia Li

    The Nethersole School of Nursing, The Chinese University of Hong Kong

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
SCREENING
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Ms.

Study Record Dates

First Submitted

October 31, 2020

First Posted

December 9, 2020

Study Start

February 1, 2021

Primary Completion

January 20, 2022

Study Completion

February 28, 2022

Last Updated

April 6, 2022

Record last verified: 2022-03

Locations